Across TCGA pan-cancer cohorts, SLC44A4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC44A4 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC44A4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC44A4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where SLC44A4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.415	0.947	.002	24	view →
LSCC	DFS	Quartile	II,III,IV	0.777	1.000	.015	11	view →
CCRCC	OS	Median	All	1.000	0.672	.011	6	view →
LUAD	OS	Tertile	III,IV	0.536	1.000	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SLC44A4 tumor-vs-normal RNA expression · all SLC44A4 data types